{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:20:49Z","timestamp":1768623649310,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.xphs.2023.09.016","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T20:48:17Z","timestamp":1695415697000},"page":"798-805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor"],"prefix":"10.1016","volume":"113","author":[{"given":"Ryosuke","family":"Watari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-8678","authenticated-orcid":false,"given":"Ryosuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1439-2431","authenticated-orcid":false,"given":"Takanobu","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2023.09.016_bib0001","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/jcph.2119","article-title":"Using endogenous biomarkers to derisk assessment of transporter-mediated drug-drug interactions: a scientific perspective","volume":"62","author":"Arya","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2023.09.016_bib0002","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cpt.1695","article-title":"Dose-dependent inhibition of OATP1B by rifampicin in healthy volunteers: comprehensive evaluation of candidate biomarkers and OATP1B probe drugs","volume":"107","author":"Mori","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2023.09.016_bib0003","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/cts.12625","article-title":"Organic anion transporter polypeptide 1B1 polymorphism modulates the extent of drug-drug interaction and associated biomarker levels in healthy volunteers","volume":"12","author":"Yee","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.xphs.2023.09.016_bib0004","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/jcph.1261","article-title":"Effect of OATP1B1\/1B3 inhibitor GDC-0810 on the pharmacokinetics of pravastatin and coproporphyrin I\/III in healthy female subjects","volume":"58","author":"Liu","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2023.09.016_bib0005","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40262-018-0648-3","article-title":"Clinical investigation of coproporphyrins as sensitive biomarkers to predict mild to strong OATP1B-mediated drug-drug interactions","volume":"57","author":"Kunze","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2023.09.016_bib0006","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1124\/dmd.120.000076","article-title":"Detection of weak organic anion-transporting polypeptide 1B inhibition by probenecid with plasma-based coproporphyrin in humans","volume":"48","author":"Zhang","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2023.09.016_bib0007","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/cpt.2593","article-title":"Effect of a ketohexokinase inhibitor (PF-06835919) on in vivo OATP1B Activity: integrative risk assessment using endogenous biomarker and a probe drug","volume":"112","author":"Tess","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2023.09.016_bib0008","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/cpt.2434","article-title":"Biomarker-informed model-based risk assessment of organic anion transporting polypeptide 1B mediated drug-drug interactions","volume":"111","author":"Kimoto","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2023.09.016_bib0009","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/psp4.12315","article-title":"Quantitative prediction of OATP-mediated drug-drug interactions with model-based analysis of endogenous biomarker kinetics","volume":"7","author":"Yoshida","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.xphs.2023.09.016_bib0010","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/psp4.12348","article-title":"PBPK modeling of coproporphyrin I as an endogenous biomarker for drug interactions involving inhibition of hepatic OATP1B1 and OATP1B3","volume":"7","author":"Yoshikado","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2023.09.016_bib0011","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/00498254.2022.2085210","article-title":"Quantitative prediction of OATP1B-mediated drug-drug interactions using endogenous biomarker coproporphyrin I","volume":"52","author":"Takubo","year":"2022","journal-title":"Xenobiotica"},{"key":"10.1016\/j.xphs.2023.09.016_bib0012","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/psp4.12849","article-title":"Cluster Gauss-Newton method analyses of PBPK model parameter combinations of coproporphyrin-I based on OATP1B-mediated rifampicin interaction studies","volume":"11","author":"Yoshikado","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.xphs.2023.09.016_bib0013","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/cts.13272","article-title":"Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs","volume":"15","author":"Mochizuki","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.xphs.2023.09.016_bib0014","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1124\/dmd.119.087924","article-title":"GDC-0810 pharmacokinetics and transporter-mediated drug interaction evaluation with an endogenous biomarker in the first-in-human, dose escalation study","volume":"47","author":"Cheung","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2023.09.016_bib0015","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1124\/dmd.118.081125","article-title":"Further studies to support the use of coproporphyrin I and III as novel clinical biomarkers for evaluating the potential for organic anion transporting polypeptide 1B1 and OATP1B3 inhibition","volume":"46","author":"Shen","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2023.09.016_bib0016","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/cts.12889","article-title":"Substantially increased plasma coproporphyrin-i concentrations associated with OATP1B1*15 Allele in Japanese general population","volume":"14","author":"Suzuki","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.xphs.2023.09.016_bib0017","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.dmpk.2018.09.003","article-title":"Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers","volume":"34","author":"Mori","year":"2019","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.xphs.2023.09.016_bib0018","unstructured":"Press release on November 22,2022. Xocova\u00ae (Ensitrelvir Fumaric Acid) tablets 125mg approved in Japan for the treatment of SARS-CoV-2 infection, under the emergency regulatory approval system. Accessed on 19 June, 2023 https:\/\/www.shionogi.com\/global\/en\/news\/2022\/11\/e20221122.html"},{"key":"10.1016\/j.xphs.2023.09.016_bib0019","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent Oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.xphs.2023.09.016_bib0020","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/jac\/dkac257","article-title":"Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model","volume":"28","author":"Nobori","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2023.09.016_bib0021","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkad027","article-title":"Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo","volume":"78","author":"Kuroda","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2023.09.016_bib0022","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/aac.00632-22","article-title":"Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults","volume":"66","author":"Shimizu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2023.09.016_bib0023","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2023.09.016_bib0024","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/ciac933","article-title":"Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study","volume":"76","author":"Mukae","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.xphs.2023.09.016_bib0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40261-023-01265-8","article-title":"Evaluation of the drug-drug interaction potential of ensitrelvir fumaric acid with cytochrome P450 3A substrates in healthy Japanese adults","volume":"43","author":"Shimizu","year":"2023","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.xphs.2023.09.016_bib0026","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/jcph.2247","article-title":"Evaluation of drug-drug interactions of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor, with transporter substrates based on in vitro and a clinical study","volume":"63","author":"Shimizu","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2023.09.016_bib0027","unstructured":"The Japanese Ministry of Health, Labour, and Welfare. Guideline on drug interaction for drug development and appropriate provision of information. February 2019. https:\/\/www.pmda.go.jp\/files\/000228122.pdf"},{"key":"10.1016\/j.xphs.2023.09.016_bib0028","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cpt.1599","article-title":"Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI","volume":"107","author":"Jones","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2023.09.016_bib0029","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/psp4.12515","article-title":"Physiologically-based pharmacokinetic model-informed drug development for fenebrutinib: understanding complex drug-drug interactions","volume":"9","author":"Chen","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.xphs.2023.09.016_bib0030","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1002\/jcph.723","article-title":"Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1","volume":"56","author":"Vaidyanathan","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2023.09.016_bib0031","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.118.253062","article-title":"Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of OATP1B inhibition compared with rosuvastatin and coproporphyrin I","volume":"368","author":"Barnett","year":"2019","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923003751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923003751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:43:45Z","timestamp":1758361425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354923003751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0022354923003751"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.09.016","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}